Search results
6 mar 2023 · Results from a study in which the growth rates of prostate tumours were modelled suggested that vaccine treatments might slow prostate cancer growth and produce better long-term outcomes...
28 paź 2024 · Within the immunosuppressive tumor microenvironment of PCa, where regulatory T cells and myeloid-derived suppressor cells inhibit immune surveillance, DC vaccines aim to overcome these immune barriers by reactivating T-cell responses, thereby strengthening the immune attack on cancer cells.
For over 30 years, growing interest has focused on the development of vaccines as treatments for prostate cancer, with the goal of using vaccines to activate immune cells capable of targeting prostate cancer to either eradicate recurrent disease or at least delay disease progression.
In the clinical realm of prostate cancer DNA vaccines, PAP has been a focal antigen, aligning with its role in the Sipuleucel-T vaccine. The pTVG-HP DNA vaccine, encoding human PAP, has been particularly noteworthy for inducing sustained PAP-specific T cell responses with a Th1-biased immune response in patients experiencing PSA recurrence of ...
28 maj 2021 · Subgroup analysis showed that the use of vaccine therapy in prostate cancer leads to significant improvement in OS (HR 0.83; 95% CI (0.74, 0.93)) and PFS (HR 0.80; 95% CI (0.67, 0.95)) compared to placebo and standard treatment.
7 sty 2014 · Current strategies at the forefront of immunotherapy for prostate cancer include therapeutic vaccines and immune checkpoint inhibitors. Therapeutic cancer vaccines are designed to stimulate immune cells to target specific TAAs overexpressed on cancer cells and are associated with minimal toxicity.
Overall, five approaches have been assessed in randomized phase III trials and sipuleucel-T was approved as a treatment for metastatic castration-resistant prostate cancer, being the only vaccine approved to date by the FDA as a treatment for cancer.
